{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.9","upperLimit":"9.7","value":"6.8"},{"groupId":"OG001","lowerLimit":"1.4","upperLimit":"6.9","value":"2.8"},{"groupId":"OG002","lowerLimit":"1.4","upperLimit":"5.7","value":"4.0"},{"groupId":"OG003","lowerLimit":"1.3","upperLimit":"5.5","value":"2.7"},{"comment":"Unable to estimate as number of events is too low.","groupId":"OG004","lowerLimit":"1.3","upperLimit":"NA","value":"1.4"},{"groupId":"OG005","lowerLimit":"3.6","upperLimit":"9.3","value":"5.2"},{"groupId":"OG006","lowerLimit":"1.4","upperLimit":"8.2","value":"3.4"},{"groupId":"OG007","lowerLimit":"2.7","upperLimit":"11.0","value":"5.5"},{"groupId":"OG008","lowerLimit":"1.4","upperLimit":"8.1","value":"4.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"171"},{"groupId":"OG001","value":"77"},{"groupId":"OG002","value":"60"},{"groupId":"OG003","value":"20"},{"groupId":"OG004","value":"21"},{"groupId":"OG005","value":"41"},{"groupId":"OG006","value":"21"},{"groupId":"OG007","value":"70"},{"groupId":"OG008","value":"45"}],"units":"Participants"}],"description":"Progression-free survival (PFS) from first dose throughout the study was estimated for all subjects (safety population) using a piecewise method.","dispersionType":"Inter-Quartile Range","groups":[{"description":"cabozantinib, 100 mg, po QD","id":"OG000","title":"CRPC"},{"description":"cabozantinib, 100 mg, po QD","id":"OG001","title":"Melanoma"},{"description":"cabozantinib, 100 mg, po QD","id":"OG002","title":"NSCL"},{"description":"cabozantinib, 100 mg, po QD","id":"OG003","title":"Pancreatic Cancer"},{"description":"cabozantinib, 100 mg, po QD","id":"OG004","title":"Gastric/GEJ"},{"description":"cabozantinib, 100 mg, po QD","id":"OG005","title":"Hepatocellular Carcinoma"},{"description":"cabozantinib, 100 mg, po QD","id":"OG006","title":"SCLC"},{"description":"cabozantinib, 100 mg, po QD","id":"OG007","title":"Ovarian Cancer"},{"description":"cabozantinib, 100 mg, po QD","id":"OG008","title":"Metastatic Breast Cancer"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"From initial dose through final study visit up to 44 months","title":"Progression Free Survival (PFS) - Throughout the Study","type":"SECONDARY","unitOfMeasure":"months"}